We are pleased to announce that MB Therapeutics has obtained the Deeptech label from BPI (Banque Publique d’Investissement). This label is associated with a turnkey solution development project for the production of personalized medicines using pharmaceutical 3D printing technology.
With the Deeptech label, BPI France aims to foster the emergence of disruptive innovation startups in France and enable their growth through dedicated support programs.
About MB Therapeutics:
Born out of a collaboration between Lynxter, a manufacturer of industrial 3D printers, and the University Hospital of Nîmes, MB Therapeutics is a startup specialized in personalized medicine based on 3D printing technology. The company aims to improve drug administration, particularly for children with illnesses, by offering a solution for producing customized pediatric oral forms in collaboration with healthcare professionals.